Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis

Wang, Xu; Hu, Bo; Shen, Hugang; Zhou, Hao; Xue, Xiaofeng; Chen, Yan; Chen, Shaoji; Han, Yongtao; Yuan, Bin; Zhao, Hong; Zhi, Qiaoming; Kuang, Yuting

doi:10.1016/j.biopha.2015.07.038

Cited by 38 publications

(29 citation statements)

References 43 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ntziachristos et al (2012) reported that Notch1 interacts with EZH2 to control gene expression and cell transformation in T-cell acute lymphoblastic leukemia. The authors of a previous meta-analysis reported that EZH2 is a putative factor in the progression of breast cancer, and overexpression of EZH2 is distinctly correlated with poor survival of breast cancer (Wang et al, 2015). In this study, we found that EZH2 is associated with the progression of breast invasive ductal carcinoma, which is correlated to the expression of Notch1.…”

Section: Discussionsupporting

confidence: 61%

Relationship between the expression of Notch1 and EZH2 and the prognosis of breast invasive ductal carcinoma

Zhao

Luan

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We determined whether the coexpression of Notch1 and EZH2 influences the progression and prognosis of breast invasive ductal carcinoma. Using the c 2 test, a significant difference was found between high and low expression of Notch1 in terms of lymph node, hormone receptor, and p53 expression (P < 0.05). Moreover, a significant difference was found between high and low expression of EZH2 in terms of tumor size, histologic grade, hormone receptor, and expression of Ki67 (P < 0.05). Using Pearson correlation analysis, we found a significant positive correlation between Notch1 and EZH2 expression in the tissue samples of breast invasive ductal carcinoma (P = 0.038). High Notch1 and EZH2 expression was associated with poor progression-free survival compared with low expression (P Notch1 = 0.000, 40.3 vs 48.9 months; P EZH2 = 0.000, 40.2 vs 49.9 months). Moreover, we found that high Notch1 and EZH2 expression was associated with poor overall survival compared with low expression (P Notch1 = 0.000, 51.2 vs 56.2 months; P EZH2 = 0.002, 51.7 vs 56.4 months). In conclusion, Notch1 and EZH2 coexpression contributes to the progression and prognosis of breast invasive ductal carcinoma.

show abstract

Section: Discussionsupporting

confidence: 61%

Relationship between the expression of Notch1 and EZH2 and the prognosis of breast invasive ductal carcinoma

Zhao

Luan

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Guo et al [30] found that EZH2 had positive association with TNM stage and lymph node metastasis in gastric cancer. Wang and colleagues showed that EZH2 was predictive for poor OS in breast cancer patients [33]. In the current meta-analysis, we revealed that EZH2 was associated with KPS score < 80, which indicated the suboptimal condition of patients.…”

Section: Discussionmentioning

confidence: 52%

EZH2 overexpression is associated with poor prognosis in patients with glioma

Zhang

Chen

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Previous studies have investigated the prognostic value of enhancer of zeste homolog 2 (EZH2) expression in patients with glioma but conclude contradictory results. We aimed to comprehensively evaluate the prognostic role of EZH2 in glioma by meta-analysis. The databases of PubMed, Embase and Web of Science were searched. Hazard ratio (HR) and 95% confidence interval (CI) were combined to assess the association between EZH2 and overall survival (OS) as well as progression-free survival (PFS). Odd ratio (OR) and 95% CI were calculated to investigate the relevance of EZH2 on clinical factors. Six studies with 575 patients were included for meta-analysis. The results showed that EZH2 overexpression was correlated with poor OS (n = 6, HR = 2.23, 95% CI: 1.56–3.19, p < 0.001) and PFS (n = 3, HR = 2.23, 95% CI: 1.56–3.19, p < 0.001). Subgroup analysis showed that EZH2 had enhanced prognostic value in Asian patients, for WHO grade I-IV and when using immunohistochemistry (IHC) method. In addition, EZH2 was associated with KPS score < 80. No evidence of publication bias was found in this meta-analysis. In conclusion, the present study showed that EZH2 was a potential prognostic marker for poor OS, PFS and lower KPS score in glioma patients.

show abstract

“…Previous integrative genomic analyses have implicated a number of transcriptional networks in breast cancer, among which several transcription factors such as the HIF1-α-and FoxM1-regulatory pathways have been found to be particularly enriched in TNBC (4,24). In addition, HIF1-α has been reported to bind to the promoters of EZH2 (25) and FOXM1 (26) to activate their expression, and all have been implicated in breast cancer invasion and metastasis (27)(28)(29). These findings suggest a possible functional convergence among these invasive drivers in TNBC progression.…”

Section: Resultsmentioning

confidence: 99%

HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer

Mahara

Lee

Feng

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Despite the established oncogenic function of Polycomb repressive complex 2 (PRC2) in human cancers, its role as a tumor suppressor is also evident; however, the mechanism underlying the regulation of the paradoxical functions of PRC2 in tumorigenesis is poorly understood. Here we show that hypoxia-inducible factor 1, α-subunit (HIFI-α) is a crucial modulator of PRC2 and enhancer of zeste 2 (EZH2) function in breast cancer. Interrogating the genomic expression of breast cancer indicates high HIF1A activity correlated with high EZH2 expression but low PRC2 activity in triple-negative breast cancer compared with other cancer subtypes. In the absence of HIFIA activation, PRC2 represses the expression of matrix metalloproteinase genes (MMPs) and invasion, whereas a discrete Ezh2 complexed with Forkhead box M1 (FoxM1) acts to promote the expression of MMPs. HIF1-α induction upon hypoxia results in PRC2 inactivation by selective suppression of the expression of suppressor of zeste 12 protein homolog (SUZ12) and embryonic ectoderm development (EED), leading to a functional switch toward Ezh2/FoxM1-dependent induction of the expression of MMPs and invasion. Our study suggests a tumor-suppressive function of PRC2, which is restricted by HIF1-α, and an oncogenic function of Ezh2, which cooperates with FoxM1 to promote invasion in triple-negative breast cancer.

show abstract

Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis

Cited by 38 publications

References 43 publications

Relationship between the expression of Notch1 and EZH2 and the prognosis of breast invasive ductal carcinoma

Relationship between the expression of Notch1 and EZH2 and the prognosis of breast invasive ductal carcinoma

EZH2 overexpression is associated with poor prognosis in patients with glioma

HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer

Contact Info

Product

Resources

About